Autolus Therapeutics PLC (NAS:AUTL)
$ 3.92 0.05 (1.29%) Market Cap: 1.04 Bil Enterprise Value: 335.67 Mil PE Ratio: 0 PB Ratio: 1.79 GF Score: 55/100

Autolus Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript

Apr 14, 2022 / 12:45PM GMT
Release Date Price: $4.04 (-1.94%)
Gil Blum
Needham & Company, LLC - Analyst

Good morning, and welcome to day four of the Needham and Company healthcare conference. My name is Gil Blum, and I am a Senior Biotech Analyst here at Needham and Company, covering the immuno-oncology and gene therapy sub-sectors. It is my pleasure to have with me today Dr. Christian Itin, CEO of Autolus. (Operator Instructions)

And with that, Dr. Itin, I think we can get started. Maybe a good place to start, for those who aren't familiar, can you remind us of Autolus's main mission, and maybe its differentiating features in its autologous CAR Ts?

Christian Itin
Autolus Therapeutics plc - CEO

First off, great to be on, and thanks for the invitation, Gil. So at Autolus, we're obviously focusing on CAR T therapies and we're looking at each indication that we're going after, really specifically of what the type of profile is that we need to have to get to transformational outcome. And for our lead program obe-cel, we're focusing on acute lymphoblastic leukemia, and particularly the adult patient population,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot